Reportlinker Adds Triple Analysis: Leukemia, Melanoma and Peptides

NEW YORK, May 4, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Triple Analysis: Leukemia, Melanoma and Peptides

http://www.reportlinker.com/p0284622/Triple-Analysis-Leukemia-Melanoma-and-Peptides.html

This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia

The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.

This part is based on the following publication:

A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Melanoma

The melanoma report part comprises defined and up to date development strategies for 218 melanoma drugs within the portfolio of 138 investigators, from Ceased to Marketed. This part extensively analyses their 170 identified drug targets, organized into 151 drug target strategies, and assesses them in eight different compound strategies in melanoma.

This part is based on the following publication:

A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market

Part III: Peptides

The peptide report part comprises defined and up to date development strategies for 145 cancer peptide drugs within the portfolio of 103 investigators, from Ceased to Marketed. This report part extensively analyses 125 identified targets of peptide drugs, organized into 103 drug target strategies, and assesses them in 52 different cancer indications.

This part is based on the following publication:

Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia

5.1 The Scope of this Report 29

6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443

7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727

8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728

9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129

11 Disclaimer 1130

12 Drug Index 1131

13 Company Index 1140

Figures: Includes 6 Figures

Tables: Includes 253 Tables

Total Number of Pages: 1,147

Part II: Melanoma

5.1 The Scope of this Report 25

6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (170 Drug Targets) 29-363

7 Emerging New Products to Established Ones: Drug Target Strategies of Melanoma Drugs by their Highest Stage of Development (151 Drug Target Strategies and 218 Melanoma Drugs) 364-538

8 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (8 Compound Strategies) 539-574

9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Investigator (138 Companies) 575-766

10 Disclaimer 767

11 Drug Index 768

12 Company Index 773

Figures: Includes 6 Figures

Tables: Includes 196 Tables

Total Number of Pages: 777

Part III: Peptides

5.1 The Scope of this Report 24

5.2 The Competitive Advantage and Disadvantage of Peptide Drugs 26

6 Consider the Therapeutic Peptide Target for the Highest Therapeutic Outcome and Return on Investment (125 Drug Targets) 29-219

7 Emerging New Products to Established Ones: Drug Target Strategies of Peptides by their Highest Stage of Development in Oncology (103 Drug Target Strategies and 145 Peptide Drugs) 220-246

8 Selecting Cancer Indications for Peptide Drugs (52 Cancer Indications) 247-300

9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Peptide Drug Pipeline in Oncology by Investigator (103 Investigators) 301-586

10 Disclaimer 588

11 Drug Index 589

12 Company Index 593

Figures: Includes 4 Figures

Tables: Includes 192 Tables

Total Number of Pages: 596

To order this report:

: Triple Analysis: Leukemia, Melanoma and Peptides

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.